GHRP-2

GHRP-2 (also known as Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102) is a prominently researched experimental compound classified strictly within the GHRP framework. Operating primarily through advanced pharmacological pathways, it functions by synthetic hexapeptide GH secretagogue acting on the GHSR1a receptor. GHRP-2 produces the most potent GH release among standard GHRPs (stronger than GHRP-6 or Ipamorelin) but with moderate increases in cortisol and prolactin. Approved in Japan as a diagnostic tool for GH deficiency (trade name: Pralmorelin/GHRP Kaken). with a documented biological half-life of roughly 1.5 hours, in preclinical investigative trials and independent academic studies, researchers utilizing GHRP-2 have documented significant, quantifiable biological outcomes, primarily focusing on strongest gh release of standard ghrps, muscle growth, anti-aging, recovery. Typical research protocols investigate administering 100 to 300mcg via subq pathways 1-3x daily. However, it is critically important to understand that while GHRP-2 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.